Treatment of acute promyelocytic leukemia (APL) blasts with cyclic adenosine monophosphate (CAMP) analogs, in combination with all-trans retinoie acid (ATRA), results in the upregulation of the expression of leukocyte alkaline phosphatase (LAP), a marker for the differentiation of the granulocyte. The synergistic interaction between the cyclic nucleotide analogs and the retinoid is not unique t o APL cells, as it is observed also in the peripheral granulocytes of chronic myelogenous leukemia (CML) patients. The molecular mechanisms underlying LAP induction were studied in NW, an immortalized APL cell line. Induction of LAP enzymatic activity is dependent on the time of exposure and on the concentrations of dibutyryl-CAMP or 8-bromo-CAMP and ATRA, two factors that influence the kinetics of appearance of detectable levels of the enzyme. Augmentation of LAP LKALINE PHOSPHATASES are a family of glycoproteins of unknown physiologic function expressed on the plasma membrane of various cell types.'-5 In the hematopoietic system, the liverhonekidney (L/B/K)-type isoenzyme, also known as leukocyte alkaline phosphatase (LAP), represents an excellent marker for the differentiation of the neutrophilic granulocyte. (Throughout this report, the alkaline phosphatase expressed in polymorphonuclear leukocytes, acute promyelocytic blasts, NB4, and other hematopoietic cells is referred to as LAP, whereas the corresponding gene is referred to as L/B/K-type alkaline phosphatase or LAP gene, indifferently.) In fact, the gene is not expressed in either the lymphocytic or the monocytic lineage. In addition, experiments performed in normal and leukemic cells representing various stages of differentiation along the myelogenous pathway indicate that LAP is expressed only in the postmitotic granulocyte.6" In the neoplastic granulocytes of chronic myelogenous leukemia (CML) patients, during the stable phase of the disease, LAP gene expression is induced by granulocyte colony-stimulating factor (G-CSF), the most important regulator of neutrophilic granulocyte differentiation and function.'j In various cell contexts, expression of the L/B/K-type alkaline phosphatase gene is regulated by alltrans retinoic acid (ATRA) and other synthetic re ti no id^,""^ which are compounds known to exert multiple and strong cytodifferentiating effects."j Acute promyelocytic leukemia (APL; M3 in the FrenchAmerican-British [FAB] classification) represents at least 10% of all the acute myelogenous leukemias in the ad~1t.l~ Cytologically, the disease is characterized by a block in differentiation along the myelogenous pathway at the level of the promyelocyte. Genetically, practically 100% of APL cases present a balanced chromosomal translocation involving chromosomes 15 and 17." The breakpoint of this translocation is known to map at the level of the second intron of the type (U receptor for retinoic acid (RAR-(U) located on chromosome 17 and the PML gene, which maps on chromosome 15.'9-22 As a consequence of this genetic defect, neoplastic blasts always express an aberrant fusion protein, PML-RAR, as well as the normal RAR-(u?"~~ Paradoxically, despite altered expression of the major form of RARs present in the hematopoietic system, the APL cell is exquisitely sensitive to the cytodifferentiating action of pharmacologic concentrations of ATRA. Indeed, APL is the only neoplastic condition where cytodifferentiating therapy with ATRA has proved successful, leading to high rates of complete clinical r e r n i s s i~n .~~~~~ Thus, this type of leukemia represents a unique tool for the study of ATRA-induced granulocytic differentiation, especially after the development of NB4, an easily cultured immortalized cell line that exhibits most of the characteristics of APL?9
levels by ATRA and CAMP is the result of both transcriptional and early posttranscriptional events and requires de novo protein synthesis. LAP induction correlates with augmentation in the levels of the type I catalytic subunit of CAMPdependent protein kinase transcript and with granulocytic differentiation. The transcriptional component of the process leading t o increased LAP gene expression was reproduced in its main features by transient transfection experiments performed in COS-7 cells using the normal retinoic acid receptor type a (RAR-a) or the APL-specific aberrant form (PML-RAR) and the upstream promoter of the liver/ bone/kidney (L/B/K)-type alkaline phosphatase gene. The promoter is upregulated by treatment with ATRA, and this upregulation is further increased by CAMP analogs. despite altered expression of the major form of RARs present in the hematopoietic system, the APL cell is exquisitely sensitive to the cytodifferentiating action of pharmacologic concentrations of ATRA. Indeed, APL is the only neoplastic condition where cytodifferentiating therapy with ATRA has proved successful, leading to high rates of complete clinical r e r n i s s i~n .~~~~~ Thus, this type of leukemia represents a unique tool for the study of ATRA-induced granulocytic differentiation, especially after the development of NB4, an easily cultured immortalized cell line that exhibits most of the characteristics of APL?9
A detailed understanding of the molecular mechanisms underlying the processes governing cell differentiation is required for a better use of ATRA alone or in combination with other cytodifferentiating agents. Studies on the regulation of a differentiation marker like LAP may be useful to understand the factors involved in the process leading to the maturation of the normal and neoplastic promyelocyte towards the granulocyte. In a recent report, we demonstrated Analysis of cell surface markers. NB4 cells were seeded at a concentration of 4 X 1@/mL in RPMI 1640 containing 10% fetal calf serum and incubated for 3 days with various concentrations of ATRA, 1 mmol/L db-CAMP, or the combination of the two compounds. The number of CDIIb-and CD33-positive cells and the mean associated fluorescence were quantitated using a FACScan analyzer (Becton Dickinson, Mountain View, CA). Determination of surface markers was performed by a direct immunofluorescence assay using the following fluorescence-conjugated monoclonal antibodies purchased from Becton Dickinson: phycoerythrin (PE)-conjugated Leu15 (IgG2a. anti-CDllb) and Leu M9 (IgG1, anti-CD33). Simultest Control (PE conjugates IgGl and IgG2a; Becton Dickinson) was used as a negative control.
Measurement of LAP activity. Approximately 1 x 10'. NB4, HL-60, and APL fresh leukemic cells or CML neutrophils were harvested, pelleted by centrifugation at 400g for 10 minutes, washed once with 0.9% NaCI, and centrifuged again. The washed cell pellet was resuspended in homogenization buffer [ l mmoVL MgCI2, 1 mmoVL CaCI,, 20 pmoVL ZnCI,, 0.1 m o m NaCI, 0. I % (voVvol) Triton X-100, and 50 mmoVL Tris/HCl, pH 7.41 and disrupted by vigorous pipetting.
The homogenate was used for the LAP assay, which was performed with p-nitrophenol phosphate (Sigma) as substrate according to the instructions of the manufacturer. LAP activity was normalized for the content of protein in the sample. Proteins were measured according to the Bradford m e t h~d '~ using bovine serum albumin fraction V (Sigma) as a standard. One unit of LAP activity is defined as the amount of enzyme capable of transforming 1 pmol of substrate in 1 minute at 25°C. Enzyme assays were performed in conditions of linearity relative to the substrate and to the concentration of proteins.
Northern blot analysis and polymerase chain reaction (PCR). Total RNA was prepared from NB4 cells and normal neutrophilic granulocytes according to a modification of the guanidium isothiocyanate/CsCI method and used for Northern blot analysis38 and PCR amplification. The probes used for Northern blot analysis were a fulb length human (L/B/K-type) alkaline phosphatase cDNA (ATCC)?9 mouse RAR-a1 cDNA (from Dr Pierre Chambon, Strasbourg, France),@ and cDNAs corresponding to the type I a or type I1 P regulatory (RIa, RII,B)4'"2 and type a catalytic subunits of the CAMP-dependent protein kinase (PKA), as well as the cDNA coding for the human glucose-6-phosphate dehydrogenase (G6PD). 44 The various probes were labeled to a specific radioactivity of 1 X IO9 to 2 X IO9 cpm/pg using hexanucleotide primers and ["P] deoxycytidine triphosphate (dCTP).45 PCR amplifications of the LAP transcripts were performed from total RNA after reverse transcription using the gene AMP kit (Cetus Perkin Elmer, Norwalk, CT), as already de~cribed.~' The antisense downstream oligonucleotide is contained in exon 2 (5' GCTTGGTCTCGCCAGTAC'JT 3' complementary to nucleotides 255 to 274 of the human UBK-type alkaline phosphatase cDNA)," whereas sense upstream oligonucleotide is specific for exon 1A (5' GCGTTGCGCTCCCGCCACTC 3', nucleotides -196/-177 of the human LISIK-type alkaline phosphatase gene)! (The most upstream leader exon of the LIBIK-type alkaline phosphatase gene is referred to as exon lA, whereas the other is referred to as exon 1B throughout this report, although the two exons were first described as 1B and lL, respectively, by Matsuura et al.& For P-actin amplification, two oligonucleotides specific for the pactin gene (5' GCGCTCGTCGTCGACAACGG 3', nucleotides 60 to 79, and 5' GATAGCAACGTACATGGCTG 3', complementary to nucleotides 430 to 449 of the human P-actin c D N A )~~ were used. After amplification, samples were run on a 1.5% agarose gel. Amplified products were transferred onto nylon membranes and detected by Southern blotting analysis using "P-labeled oligonucleotides specific for exon 1A (5' TCGCCAGTGCTCTGCGCA 3'. nucleotides
For personal use only. on November 11, 2017 . by guest www.bloodjournal.org Nuclear transcription run-on assay. Nuclear transcription Nnon assay was performed as described by Eick and B0rnkamm.4~ Plasmids used for the experiments were. pBluescript (Stratagene, La Jolla, CA), G6PD," and LIBK-type alkaline phosphatase cDNAs." Autoradiograms of nuclear run-on assays were quantitated by laserscanning densitometry with a laser beam densitometer (300 A computing densitometer Fast Scan; Molecular Dynamics, Sunnyvale, CA).
Determination of intracellular CAMP levels. NB4 cells (4 X l@/ mL) were incubated for various periods of time with medium alone or medium containing db-CAMP, 8Br-cAMP, forskolin, PGEI, ATRA, or combinations of intracellular CAMP elevating agents and retinoids. All treatments were performed in the presence of a cocktail of compounds that inhibit phosphodiesterase: isobutyl-methyl xanthine (IBMX; Sigma) and Ro20-1724 (Hoffmann-La Roche, Basel, Switzerland) at a final concentration of 0.2 and 0.02 mmoVL, respectively. cAMP was extracted from cells in suspension (1.4 X IO6 cells) twice with 0.5 mL of ice-cold 70% (voUvol) ethanol in water. The two combined extracts were evaporated under vacuum and resuspended in 100 pL of distilled water. Total intracellular cAMP was measured with a specific radioimmunoassay (Amersham, Little Chalfont, UK) according to the instructions of the manufacturer.
Assays were run in duplicate on 10 pL of the extract.
Transfection experiments. Simian COS-7 fibroblasts were obtained from ATCC and routinely passaged in Dulbecco's modified Eagle's medium (DMEM) containing 10% FCS. Transient transfection experiments were performed according to a standard calciumphosphate coprecipitation procedure5' using the following plasmids:
pSG5-RAR-a (from Dr P. G. Pelicci, Perugia, Italy)22; pSG5-PMLRARaz2 and pSG5-RXR-a (from D r J. Grippo, Nutley, NJ)?' containing the human RAR-a, PML-RAR, and RXR-a cDNAs under the control of the SV-40 early T-antigen promoter enhancer; TRE-TK-CAT, containing the chloramphenicol acetyl transferase (CAT) gene under the control of a palindromic synthetic retinoic acid responsive element (RARE) placed in front of the viral thymidine kinase gene2*; psVALBKcat, containing approximately 4,500 bp of the 5' flanking region of the upstream exon of the L/B/K-type alkaline phosphatase gene placed in front of the CAT reporter (from D r Kadesch, Philadelphia, PA)"; and pnlsLACZ, containing the bacterial P-galactosidase gene under the control of the early T-antigen of the SV40 enhancer-promoter (from Dr A. Weisz, Naples, Italy)." Briefly, 50 ng each of RAR-a or PML-RAR and RXR-a were cotransfected with 1 pg of the reporter gene (TRE-TK-CAT or psVALBKcat), 0.5 pg of pnlsLACZ; and pBluscript to 10 pg. After leaving the DNA coprecipitate in contact with cells for 16 hours, fresh medium (10% charcoal stripped FCS, to eliminate endogenous retinoids) alone or fresh medium containing 8Br-CAMP, ATRA, or the combination of the two compounds was added, and cells were further incubated for 36 hours. At the end of the treatment, cells were harvested and processed for determination of CAT and Pgalactosidase activity. CAT and p-galactosidase activities were measured on cell extracts according to standard procedures" and as de~cribed?~ respectively. The results are expressed as relative CAT activity, which is the ratio of CAT activity produced by the reporter in counts per minute of acetylated chloramphenicol, divided by the B-galactosidase activity produced by pnlsLACZ expressed in absorbance units at 405 nm. enzymatic activity. The effects of db-CAMP, the stable and cell-permeable analog of the cyclic nucleotide, on LAP enzymatic activity in freshly isolated APL blasts, CML peripheral granulocytes, and the two APL-derived cell lines HL-60 and NB4 were studied in the presence and in the absence of ATRA. As shown in Table 1 , in basal conditions, the various leukemic cells express different levels of LAP. However, these levels are very close to the limit of detection of the enzymatic assay, except for in APL patient 2 and CML patients 3 and 4, which show relatively high constitutive levels of the enzyme. After treatment with db-CAMP (1 mmoVL) for 3 days, LAP is significantly (P < .01) induced only in the granulocytes of CML patients 1 and 4. If APL cells are treated for 3 days with ATRA (lo-' mom), no statistically significant increase in LAP activity is observed, in accordance with our previous report. 30 In one of four CML cases (patient 4), the retinoid causes a substantial induction of LAP enzymatic activity. Simultaneous treatment with the combination of db-CAMP and ATRA results in a significant elevation in the levels of LAP in APL, CML, and NB4 cells. The highest increase is observed in the last cell type. Surprisingly, despite the ability of HL-60 cells to differentiate in the presence of retinoid or cAMP anal0gs,3~.'~ upregulation of LAP activity is not observed after treatment with the db-CAMP and ATRA combination. Similarly, the treatment of two recently isolated ATRA-resistant NB4 clones, NB4.306" and NB4.007/6 (this latter clone was derived, without a mutagenesis step, by sequential passage of NB4 in medium containing ATRA; C. Gambacorti-Passerini, personal communication, July 1994), with the two-compound combination, does not result in increased LAP activity (data not shown).
RESULTS
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The effect of treatment with db-CAMP, ATRA, or dbcAMP + ATRA on the proliferation and the viability of myeloid leukemic cells was investigated using blasts from another APL case. In addition, on the same cells, we checked the specificity of the cAMP effect on LAP activity by substituting db-CAMP with another cell-permeable analog, 8Br-CAMP. The dibutyryl analog of cAMP is known to be hydrolized inside the cell and to release butyrate, which possesses differentiating activity on a large spectrum of cells.
When freshly isolated APL blasts are seeded at 4 X 105/mL and incubated for 3 days in the presence of medium alone, the number of cells is increased about 1.7-fold. As shown in Fig 1A and B, after incubation for 3 days, db-CAMP inhibits the growth of APL cells slightly more than 8Br-cAMP and possesses a very mild cytotoxic effect that is not observed with the latter compound. The same experiment with ATRA mom) shows that the retinoid has basically no effect on the number and viability of cells. No significant effect on cell growth or viability is evident in APL blasts treated with the combination of ATRA and dbcAMP or 8Br-CAMP. This demonstrates that ATRA has positive trophic effects on cells treated with the cAMP analogs. In terms of LAP regulation, as shown in Fig lC, neither dbcAMP nor 8Br-CAMP is capable of inducing the enzyme in our experimental conditions. However, when one of the two compounds is combined with ATRA, increases in the levels of LAP are evident after 3 days of treatment. In the blasts of this particular APL case, the dibutyryl analog of cAMP and the 8-bromo derivative are equally potent in inducing LAP. The effect of the G-CSF + ATRA treatment for 3 days is shown as a comparison, and it demonstrates that induction of LAP is quantitatively similar after challenge of APL cells with the cyclic nucleotide analogs or the cytokine, in the presence of an optimal concentration of the retinoid. Table 1 , after challenge with db-CAMP and ATRA, NB4 cells show LAP induction of the same order as observed in freshly isolated leukemic blasts. These cells are the most sensitive targets for the activity of the two compounds and were, therefore, selected to characterize the synergism between the cyclic nucleotide and the retinoid. As shown in Fig 2A, incubation of NB4 cells with medium, ATRA, or db-CAMP for 3 days does not lead to the expression of significant levels of LAP enzymatic activity. If cells are continuously treated for 3 days with ATRA and increasing concentrations of db-CAMP, a dose-dependent upregulation of LAP enzymatic activity is observed between 0.5 and 3 mmom. Similarly, as shown in Fig 2B, if dbcAMP is kept constant and the concentration of ATRA is varied, LAP enzymatic activity is dose-dependently induced between 10" and moVL. To determine the relationship between induction of LAP activity and cell growth, the effects of db-CAMP (1 mmoVL) on the proliferation and viability of NB4 cells were studied in the absence and presence of ATRA mom), and the results are shown in Fig 3A and B, respectively. When NB4 promyelocytes are cultured in the presence of medium alone for up to 3 days, an almost linear increase in the number of cells is observed. ATRA, at a concentration of m o m , causes minor cytostatic effects between the second and third day of culture. Treatment of NB4 cells with 1 mmol/L dbcAMP results in a dramatic inhibition of cell growth that becomes apparent between days 2 and 3. This effect is not augmented by the addition of ATRA. The inhibition of cell proliferation triggered by db-CAMP is not accompanied by major cytotoxic effects, as cell viability is only marginally reduced relative to control conditions. The time course for the induction of LAP in NB4 cells by the combination of dbcAMP and ATRA is presented in Fig 3C. A linear increase in the specific activity of the enzyme is evident between 1 and 3 days of culture only when the retinoid and the cAMP analog are simultaneously present in the growth medium.
Significant decreases in cell viability do not allow the study of LAP enzymatic activity after treatment with 1 mmom db-CAMP, m o m ATRA, or the combination of the two compounds beyond the third day. To determine the effects of cAMP congeners and ATRA on cell growth, viability, and LAP activity at later time points, db-CAMP was substituted by the less toxic analog 8Br-cAMP, and the concentration of the two compounds was decreased. In the presence of ATRA at lo-' m o m , 8Br-CAMP induces substantial amounts of LAP after 3 days of treatment ( Fig 5A) . As shown in Table 2 In the subsequent days, the increase in LAP activity is almost linear, regardless of the cyclic AMP analog and ATRA concentrations. These data, along with the results presented in Fig 3C , demonstrate that the kinetics of LAP induction are dependent on the exposure time as well as the concentrations of the CAMP analog and the retinoid. In the experimental conditions presented in Table 2 , 8Br-CAMP is both cytostatic and cytotoxic, although the drop in viability that appears after 4 days of treatment is delayed relative to that observed with 1 mmom db-CAMP (data not shown). ATRA, at both the concentrations used, is slightly cytostatic and becomes cytotoxic after 5 days of treatment, possibly through an apoptotic m e~h a n i s m .~~ When NB4 cells are challenged with the combination of ATRA and 8Br-cAMP, cell growth is similar to that observed after treatment with the cyclic nucleotide alone, whereas viability is more similar to that found after treatment with ATRA alone. Nevertheless, differences in cell growth and viability among the various experimental groups do not affect the interpretation of the results on LAP activity. In fact, separation of viable cells from dead or damaged cells on Percoll gradients demonstrates that more than 90% of the LAP enzymatic activity measured after treatment For personal use only. on November 11, 2017 . by guest www.bloodjournal.org From
;"E T g
; . The gene coding for the LiBIK-type alkaline phosphatase contains two leader exons, 1A (about 30 kb upstream from exon 2) and 1B (about 4 kb upstream from exon 2). It has the potential to produce two alternatively spliced mRNAs differing in their 5' untranslated region^.^^,^^,^' As the probe used for the Northern blot analysis does not distinguish the two transcripts, RNA extracted from NB4 promyelocytes ; ; mixture was split in three identical aliquots and PCR-amplified using oligonucleotide couples specific for LMK-type alkaline phosphatase exons 1A and 16 and for p-actin. respectively. As a negative control, a blank sample (H,O) was reverse-transcribed and PCR-amplified exactly as above. The products of the amplification were run on a 1.5% agarose gel, blotted on nylon membranes, and hybridized t o 32P-labeled synthetic oligonucleotides specific for alkaline phosphatase exons 1A and 16 and p-actin, respectively. The oligonucleotides used for the hybridization were distinct and internal to the couple of oligonucleotides used for the amplification step. The expected sizes of the ampliiied products are 294 and 389 bp for L/B/K-typelalkaline phosphatase exon 1A and p-actin, respectively, as indicated on the left side. The results obtained with exon 16-specific oligonucleotides were negative, and they are not shown in the figure.
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grown in medium alone and in medium containing db-CAMP, ATRA, or the two compounds in combination was used to amplify specifically the LAP mRNAs containing exon 1 A and exon IB by reverse transcription-PCR (RT-PCR). Fig 4B (data not shown) .
A long-lasting increase in the intracellular levels of CAMP is necessary for the induction of LAP. The effect of various cAMP analogs and compounds that increase the intracellular levels of the cyclic nucleotide through different mechanisms on LAP expression in NB4 cells was investigated. As shown in Fig 5A, only db-CAMP and 8Br-CAMP are capable of synergizing with ATRA, and both result in the appearance of high levels of LAP enzymatic activity. The dibutyryl analog of cAMP is more potent than 8Br-CAMP in inducing the enzyme. Forskolin, a direct activator of adenylate cyclase, and PGEI, a prostaglandin acting on a receptor coupled to the cAMP system through G-proteins. do not have any effect on LAP activity, either in the absence or in the presence of ATRA. Similarly, cholera toxin and prostaglandin E2. two other cAMP inducers, do not upregulate LAP (data not shown). As shown in Fig 5B, Northern blot analysis confirms the results obtained after measurement of enzymatic activity for db-CAMP, 8Br-CAMP, and forskolin. Forskolin treatment does not lead to the appearance of the LAP transcript, even in the presence of a cocktail of phosphodiesterase inhibitors (IBMX).
In an attempt to understand why forskolin and PGEl are ineffective in inducing LAP, the levels of intracellular cAMP were measured in NB4 cells treated with the various stimuli described above. As shown in Table 3 , the intracellular concentration of CAMP is relatively constant if cells are cultured for I O minutes or 24 hours in the presence of medium alone. The cAMP analogs db-CAMP and 8Br-CAMP cause a dramatic and long-lasting increase in the levels of this intracellular second messenger molecule. Treatment of cells with PGEI does not lead to an increase in the amounts of CAMP, whereas forskolin induces a transient augmentation that is evident at I O minutes and disappears after 24 hours. However, the increases in cAMP levels, triggered by the direct activator of adenylate cyclase, are approximately two orders of magnitude lower than those observed after db-CAMP or 8Br-CAMP treatment. The addition of ATRA does not significantly influence the levels of cAMP at any time point and in any experimental condition considered. These data demonstrate that NB4 cells are refractory to PGE I , perhaps because of lack of specific receptors, whereas they respond to forskolin with an increase in intracellular CAMP. However, the levels of the cyclic nucleotide are too low and do not last long enough to trigger LAP induction.
Induction of LAP mRNA l y CAMP and ATRA has both a transcriptional and posttranscriptional component. Cyclo- are contemporaneously added to the medium containing dbcAMP and ATRA. These data demonstrate that de novo protein synthesis is required for the upregulation of the LAP transcript. Furthermore, the increase in the steady-state levels of this mRNA after treatment with the retinoid and the cAMP analog is, at least partially, the consequence of transcriptional effects.
To more directly verify the effects of db-CAMP, ATRA, CHX, or the various combinations of the three compounds on the transcriptional rate of the gene coding for LAP, nuclear run-on experiments were performed. Figure 6B shows a representative nuclear run-on assay for the LAP and the G6PD genes, after treatment of NB4 cells for I day with medium, ATRA (IO-' mol/L), db-CAMP ( I mmol/L), or a combination of the retinoid and the cyclic nucleotide analog in the presence or absence of CHX. One-day treatment was NB4 cells were treated with medium alone, PGEl (10 pmol/L), forskolin (100 pmol/L) 8Br-CAMP (1 mmol/L), and db-CAMP (1 mmol/L) in the presence (+) and in the absence (-) of mol/L ATRA for the indicated amount of time. At the end of the treatment, cells were processed for the determination of intracellular cAMP levels. Each result is the mean t SD of three cultures.
The results are the sum of intracellular cAMP and db-CAMP or 8Br-CAMP levels, as the three compounds show very similar affinities for t Significantly higher relative to the respective medium or ATRA value ( P i .01 according to the Tukey's test after one-way analysis of the CAMP-binding protein used in the assay, as assessed by calibration curves performed with pure standards.
variance).
For personal use only. on November 11, 2017. by guest www.bloodjournal.org selected because Northern blot analysis (Fig 4A) showed that significant LAP mRNA levels are already present at this time point, and the curve of LAP mRNA induction is in its linear phase, where the transcriptional activity of the LAP gene should be at or close to its maximum. G6PD was chosen as a reference to assess the specificity of the changes in the transcription of the LAP gene, because, as shown in Fig 6A. the corresponding steady-state mRNA levels are relatively 3627 constant in NB4 cells in all the experimental conditions tested. Negligible transcription of the LAP gene (evident only after longer exposure of the autoradiogram) is observed when cells are incubated in medium alone or medium containing db-CAMP at 1 mmol/L. Treatment with ATRA results in a dramatic elevation of the LAP gene transcriptional rate. This rate of transcription is further increased when cells are challenged with the combination of db-CAMP and ATRA. Densitometric analysis of the LAP run-on signals, after normalization for the transcriptional activity of the G6PD gene, demonstrate a 1.5-fold increase after treatment with dbcAMP + ATRA relative to ATRA alone. The effect is small but reproducible, as it was observed on duplicate filters hybridized with the same radioactive nuclear RNA preparations. Furthermore, in a second and independent experiment, treatment of NB4 cells with db-CAMP + ATRA resulted in a 1 %fold elevation in the LAP run-on signal over that seen after treatment with the retinoid alone. The effects observed are specific for the LAP gene, as the G6PD run-on signal is left substantially unaffected by the various treatments. although CHX reduces it to a certain extent. Incubation of NB4 cells for I day with CHX at a concentration of 1 pg/mL almost completely abolishes the LAP gene transcriptional activation induced by ATRA or db-CAMP + ATRA. These data demonstrate that de novo protein synthesis is required for the upregulation of the LAP transcript.
ATRA increases the promoter activity qf the UB/K-ope alkaline phosphatase gene in the presence of both RAR-a and PML-RAR, and this effect is stimulated by cAMP analogs. To study possible direct interactions between CAMPand ATRA-dependent pathways at the level of the gene promoter that is responsible for the expression of LAP, transient transfection assays were performed. These experiments were performed by cotransfecting RAR-a or PML-RAR with the 5' flanking region of the human L/B/K-type alkaline phosphatase gene (approximately 4,500 bp) fused to the bacterial CAT gene as a reporter (psVALBKcat). Transfections were conducted in COS-7 cells, which are widely used to study the direct effects of retinoid receptors on responsive promoter8 as they express low levels of the endogenous retinoid receptors. All the experiments were performed in the presence or in the absence of the retinoid accessory receptor RXR-a, although only results obtained with RXR-a are presented as we did not observe significant effects of this protein on the pattern of CAT expression.
In this series of experiments, we initially used a low concentration of ATRA (IO-' mol/L), so as to highlight possible synergistic interactions between the retinoid and cAMP analogs. As shown in Fig 7A, in the presence of RAR-a, constitutive expression of CAT activity driven by the psVALBKcat construct is low but detectable. The baseline level of expression is higher in the presence of PML-RAR. After treatment with ATRA (IO-' mol/L), CAT activity is increased approximately threefold in the presence of RAR-a. In this particular experiment, PML-RAR is at least equally potent as RAR-a in activating the LAP promoter in a ligand dependent way. The cyclic nucleotide analog 8Br-CAMP causes a slight increase in CAT activity in the presence of both RAR-a ( I S-fold stimulation) and PML-RAR (two- The synergistic interaction between cAMP analogs and ATRA is also observed when using two artificial transcriptional units containing different versions of RARE placed in front of the core promoter of the viral thymidine kinase gene. As shown in Fig 7C, after transfection with TRE(2)-TK-CAT, a plasmid containing two copies of a palindromic RARE, COS-7 cells express low levels of CAT activity in basal conditions, regardless of the presence of RAR-a or PML-RAR. As expected, after treatment with ATRA (lo-' mol/L), a marked increase in CAT activity is observed in cells transfected with both RAR-a and PML-RAR (nineand eightfold induction, respectively). The cyclic nucleotide analog 8Br-CAMP alone has no effect on CAT expression. When cells are treated contemporaneously with 8Br-CAMP and ATRA, 21-and 10-fold stimulation of CAT activity is observed in the presence of RAR-a and PML-RAR, respectively. Similar results were obtained if TRE(2)-TK-CAT was substituted with the construct DRS[wt]-CAT containing two copies of the direct-repeat type RARE present in the RARp gene6' (data not shown). ATRA, 8Br-cAMP, or a combination of the two compounds does not increase the activity of the 0-galactosidase construct used to normalize the results of the transfection experiments (data not shown). Furthermore, the two compounds do not modulate the levels of CAT activity resulting from cotransfection of pSV2-CAT, a construct containing the W 4 0 enhancer-promoter, with RAR-a, PML-RAR, and RXR-a (data not shown). These results demonstrate that cross-talk between cAMP and the retinoid requires at least a functional RARE and is independent of the promoter context.
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Regulation of the mRNAs encoding RARs and PlyA subunits by the combination of db-CAMP and ATRA. Although direct effects of cAMP on the ATRA-induced transcription of the L/B/K-type alkaline phosphatase promoter are evident (Fig 7) , they may not completely explain the cross-talk be- tween the retinoid and the cyclic nucleotide observed in NB4 cells. Thus. we decided to study the effects of db-CAMP, ATRA, or a combination of the two compounds on the expression of the first components of the retinoid and PKA signalling systems.
As shown in Fig 8A. in basal conditions, NB4 cells express two forms of the normal RAR-a allele and the PML-RAR aberrant transcript. After treatment for 3 days with dbcAMP or ATRA alone, the expression of the three transcripts is not significantly affected. Incubation with the combination of the two compounds leads to an approximately twofold induction in the expression of the higher-molecular-weight normal RAR-a transcript and a fivefold increase in the PML-RAR mRNA. as determined by densitometric analysis of the autoradiogram and normalization for the expression of the G6PD transcript. This result is consistent in two other independent experiments.
PKA exists as type I and type I1 isozymes that are distinguished by their different regulatory subunits (RI and RII) that interact with an identical catalytic subunit (C)."' Among the various RI, RII, and C isoforms, Rla, RIIP. and C a seem to be important for the growth and differentiation of myelogenous leukemic cells."'"4 As shown in Fig 8B, the transcript coding for the C a subunit of PKA is constitutively expressed in NB4 cells. After treatment with ATRA for 3 days. expression of the transcript is downregulated approximately twofold. Either alone or in the presence of the retinoid, the dibutyryl analog of cAMP has no effect on the levels of this transcript. At earlier time points, the levels of C a message are constant, regardless of treatment with ATRA or cAMP analogs alone or in combination. Similarly, and as documented in Fig 8C, R I a mRNA is expressed in basal conditions, and the amounts of this transcript are left unchanged by treatment for 3 days with ATRA or db-CAMP alone. If cells are incubated simultaneously with the combination of ATRA + db-CAMP, an approximate fivefold induction in the amounts of Rla mRNA is observed starting from the first day of culture and remains constant until 3 days. The mRNA encoding RIIP is not expressed in basal conditions and after treatment with db-CAMP or ATRA alone for 3 days. Treatment of NB4 cells with the combination of ATRA + db-CAMP leads to the appearance of an RI1 transcript after 2 days in culture (barely visible in Fig 8C) , and this transcript is further increased after 3 days. The pattern of expression of R I a and RI10 observed in HL-60 is also shown. as this cell line does not respond to ATRA and dbcAMP with respect to upregulation of LAP ( Table 1) . R I a mRNA levels are only marginally affected ( I .6-fold increase in the experiment shown; 1.2-fold in a separate experiment) by treatment for up to 3 days with the cAMP analog and the retinoid, whereas the RIIb transcript, which is highly expressed in basal conditions, completely disappears after 2 days.
db-CAMP modulates ATRA-induced expression of CD1 I h
and directly regulates the levels of CD33 in NB4 cells. To study the effect of db-CAMP on the differentiation of NB4 induced by ATRA, the cells were analyzed for the expression of CD1 Ib and CD33, late and early markers of myeloid differentiation, respectively. The data shown in and 10" mol/L, a clear shift towards the right in the population of CD33-positive cells is observed after addition of db-CAMP. This effect is due to the combination of db-CAMP and ATRA, as the cyclic nucleotide analog alone has no effect on the expression of CD33 (data not shown). ATRA (IO" m o m ) and the combination of the retinoid and the cAMP analog are equally effective at reducing the expression of CD33. The profile of fluorescence observed after incubation of NB4 cells with an irrelevant antibody of the same isotype as that of the monoclonal antibodies specific for CD1 lb and CD33 is shown for comparison and demonstrates that background fluorescence is very low in the various experimental conditions considered. Our data demonstrate that, in terms of both C D l l b and CD33 expression, db-CAMP is capable of lowering the concentration of ATRA necessary to induce differentiation. Furthermore, our data show that this effect is observed at concentrations of db-CAMP and ATRA that are effective in inducing LAP expression (Fig 2) .
DISCUSSION
In this study, we report on a strong synergistic interaction between cAMP analogs and ATRA in the induction of LAP, one of the most specific markers for the terminal differentiation of the granulocyte.6-* This interaction is evident in freshly isolated APL blasts and in NB4, a recently established cell line that is a unique experimental model for this type of le~kemia.'~ ATRA and cAMP analogs induce LAP enzymatic activity also in circulating granulocytes obtained from four cases of CML during the stable phase of the disease. By contrast, two recently developed ATRA-resistant NB4 clones are unable to upregulate the expression of LAP after treatment with db-CAMP and ATRA. Furthermore, induction of LAP is not observed in HL-60 cells, which are known to undergo granulocytic differentiation in response to separate activation of the ATRAs6 and cAMP pathway^.'^.'' Collectively, these observations indicate that induction of LAP by cAMP analogs and the retinoid is not peculiar to APL blasts. In addition, our data demonstrate that sensitivity to ATRA and/or cAMP is necessary but not sufficient for the induction of LAP, suggesting that the cell context play an important role in the upregulation of this postmitotic granulocyte marker.
The mechanisms underlying the induction of LAP by cAMP and ATRA were extensively studied in NB4, as these cells proved to be extremely sensitive to the combination of the two compounds. In NB4 cells, increases in the levels of LAP enzymatic activity are the consequence of a high and long-lasting augmentation in the amounts of intracellular CAMP, which is achieved by cell-permeable cyclic nucleotide analogs and not by other adenylate cyclase activators. Induction of the enzyme is dependent on the concentration of ATRA and cAMP and on the time of exposure to the combination of the two compounds. Furthermore, LAP induction is correlated with an enhancement by cAMP analogs of the granulocytic differentiation program triggered by ATRA. In fact, relative to ATRA alone, the combination of ATRA + db-CAMP increases the expression of CD1 lb, a
For personal use only. on November 11, 2017 . by guest www.bloodjournal.org From molecule present on the cell membrane of mature granulocytes, whereas it decreases the levels of CD33, a marker of early myeloid precursor cells. The data obtained on the expression of these two cell-surface markers suggest that the cyclic nucleotide analogs either accelerate the ATRAdependent process of granulocytic differentiation or decrease the effective concentration of the retinoid necessary to achieve a cytodifferentiating effect. However, it is worthwhile to underscore the fact that ATRA-dependent morphologic differentiation of NB4 and freshly isolated APL blasts is incomplete and does not go beyond the stage of metamyelocytes and band cells. This is consistent with the fact that differentiation surface antigens specific for the polymorphonuclear stage, like CD16, are not expressed even after several days in culture with the retin0id.6~ Similarly, the biochemical differentiation of NB4 cells observed in the presence of ATRA and cAMP analogs is partial, at least as judged by the lack of expression of CD16, a surface marker always present on normal and fully differentiated granulocytes. Nevertheless, it is tempting to speculate that ATRA overcomes the differentiation block in NB4 cells beyond the promyelocyte stage, and cAMP analogs like G-CSF3' cause a further maturation towards a stage of differentiation that is biochemically closer to the mature granulocyte.@ This intermediate differentiation step may be marked by the appearance of LAP. It remains to be established whether this theory is correct and whether LAP is causally related to or has any functional role in the induction of granulocytic differentiation in NB4 cells.
Increases in the levels of LAP enzymatic activity are the consequence of a relatively rapid accumulation of the corresponding transcript, which is caused by a combination of transcriptional and posttranscriptional effects. After 1 day of treatment, nuclear run-on assays demonstrate that ATRA is responsible for a major increase in the transcriptional rate of the gene coding for LAP, and the effect is further enhanced by cAMP analogs. Interaction between the retinoid and cAMP at the transcriptional level is further supported by transient transfection experiments conducted in the presence of RAR-a, PML-RAR, and the LAP gene promoter (Fig 7) . This indicates that cross-talk between cAMP and ATRA at the transcriptional level is a necessary component of the LAP mRNA upregulation process. Our data indicate that ATRA alone is responsible for approximately 30% to 70% (as assessed by transfection and run-on experiments, respectively) of the LAP gene transcriptional activation that is caused by the combination of the retinoid and the cAMP analog. This remarkable ATRA-dependent elevation in the transcription of the LAP gene is not evident after 3 days of treatment, as reported in a previous study on the synergism between G-CSF and ATRA." This implies that ATRA causes a transient but substantial elevation in the transcriptional level of the LAP gene, which returns to baseline by 3 days. In the absence of other regulatory mechanisms, this phenomenon should lead to the appearance of measurable amounts of the LAP transcript. However, a detectable level of LAP mRNA after treatment of NB4 cells with ATRA alone is never observed. LAP mRNA accumulation is evident only after treatment of NB4 promyelocytes with the combination of ATRA and cAMP analogs. Thus, besides cooperation with the retinoid at the transcriptional level, CAMP must be responsible for some other effects involved in the upregulation of LAP gene expression. Posttranscriptional stabilization of the LAP nuclear pre-mRNA or the corresponding mature cytosolic transcript by cAMP is possible. A CAMP-dependent effect on the stability of cytoplasmic LAP mRNA is unlikely, given the long half-life of the message: whereas an early posttranscriptional stabilization of the nuclear pre-mRNA is more plausible. With respect to this, it is known that early posttranscriptional events are playing an important role in the upregulation of L/B/K-type alkaline phosphatase gene expression in cells other than APL blasts." LAP mRNA induction by the combination of cAMP and ATRA requires de novo protein synthesis, as suggested by Northern blot assays performed in the presence of CHX. However, this effect does not seem to be related to inhibition of the synthesis of short-lived proteins involved in the putative posttranscriptional stabilization process of LAP premRNA. In fact, treatment of NB4 cells with CHX completely blocks the upregulation of LAP gene transcription triggered by ATRA or ATRA + CAMP, as assessed by nuclear runon assays. At present, we do not know whether this effect is due to a suppression of short-lived trans-acting inhibitors or induction of activators that are important for the transcriptional regulation of LAP gene in NB4 cells.
G-CSF, like cAMP analogs, interacts with ATRA in the induction of LAP at the level of NB4 cells and freshly isolated APL blasts.30 As G-CSF has been reported to elevate intracellular cAMP in acute myelogenous leukemia (AML) cells, it is important to establish whether the cyclic nucleotide has any role in the cross-talk between the cytokine and the retinoid. However, G-CSF treatment of NB4 cells does not lead to an accumulation of the intracellular levels of CAMP above baseline. Furthermore, LAP gene upregulation by G-CSF and ATRA is not blocked by a specific inhibitor of Collectively, these results suggest that increases in the intracellular levels of cAMP do not mediate the synergism between the cytokine and the retinoid. Nevertheless, recently obtained datab8 suggest that the two intracellular pathways interact at a certain level, as the combination of the three compounds leads to a synergistic augmentation of LAP in NB4 cells.
Many of the biologic effects triggered by retinoids are receptor-mediated. It is, thus, important to establish whether and which type of RARs are involved in the induction of LAP by the combination of ATRA and CAMP. NB4 cells express RAR-a and PML-RAR simultaneously and constitutively, and the mRNAs coding for the two receptors are upregulated by treatment with the retinoid and the cyclic nucleotide analogs. RAR-a may be involved in the ATRAinduced differentiation of APL cells, whereas PML-RAR is believed to play a dual role. On one hand, the aberrant receptor is considered to be responsible for the differentiation block observed in this type of leukemia. On the other hand, and paradoxically, PML-RAR is also considered to be important for the peculiar sensitivity of APL cells to the cytodifferentiating action of ATRA.69,70 The former effect may For personal use only. on November 11, 2017 . by guest www.bloodjournal.org From be explained by a dominant negative phenomenon of the protein on the RAR-, vitamin D3 receptor (VDR)-, and RXRdependent intracellular pathway^.^' The latter effect is perhaps the consequence of the ability of PML-RAR to activate the transcription of RARE-containing genes, after interaction with ATRA.7' Transient transfection experiments demonstrate that the LAP gene is a potential target for PML-RAR. They also show that both RAR-a and PML-RAR can activate the LAP promoter in the presence of ATRA or ATRA + cAMP analogs (Fig 7) . These data do not allow us to established whether RAR-a, PML-RAR, or both receptors are involved in the upregulation of LAP in NB4 cells, and further experiments are required to directly address this question. At present, it is even more difficult to assess whether the observed increase in PML-RAR and RAR-a transcripts, after treatment of NB4 cells with the combination of' ATRA and cAMP analogs, has any relevance for the increased expression of the LAP gene. However, this effect may be significant for other aspects of the granulocytic differentiation program caused by ATRA and cAMP in NB4 cells.
The CAMP-dependent kinase PKA is the main transducer of the biochemical signals leading to an elevation in the levels of the intracellular cyclic nucleotide.
In NB4 cells, LAP induction is completely dependent on PKA, as accumulation of the transcript coding for the enzyme is blocked by a specific competitive inhibitor of the cyclic nucleotideactivated kinase.'* Furthermore, after treatment with dbcAMP + ATRA, we observed both quantitative and qualitative changes in the mRNAs coding for the regulatory and catalytic subunits of the PKA enzymatic system. These changes are characterized by a relatively rapid accumulation of the transcript coding for RIa, followed by a much slower appearance of RIIP, and by a downregulation of C a mRNAs. Appearance of the RIIP message is dissociated from LAP upregulation, and C a downmodulation is inversely correlated to LAP expression. Hence, these two effects are irrelevant for LAP induction. By contrast, it is conceivable that the increase in the levels of RIa transcript is associated with and may play a role in the induction of LAP, although it remains to be demonstrated that changes in mRNA levels are followed by translation of the transcript into active proteins. It is interesting that R1a induction is much lower (if at all present) in HL-60 cells after treatment with ATRA + db-CAMP, and this correlates with the lack of LAP induction in this particular cell type. Upregulation of RIa during the process of granulocytic differentiation, which is accompanied by growth inhibition in NB4 cells, is, by itself, an interesting finding. In fact, in HL-60 promyelocytes, upregulation of RIa is related to cell proliferation, whereas increased expression of RIIP mediates cytodifferentiation.h2M It is conceivable that the two regulatory subunits of the kinase have different roles in NB4 and HL-60 cells, which represent different stages along the myeloid maturation process.
As a first step in the definition of the cis-and trans-acting elements involved in the transcriptional component of the process leading to the upregulation of LAP gene expression by ATRA and CAMP analogs, constructs containing an appropriate reporter under the control of the LAP promoter were used in transient transfection assays. These experiments were performed by overexpression of RAR-a and PML-RAR in COS-7 cells, and they reproduced the most relevant features of the transcriptional component underlying LAP mRNA induction in NB4 cells. In this experimental model, the transcriptional activity of the LAP promoter is directly upregulated by both RAR-a and PML-RAR in a ligand-dependent way, and analogs of CAMP are capable of synergistically increasing the transactivation potential of the two receptors significantly. Thus. the CAT construct seems to contain all the regulatory elements that are involved in the transcriptional activation of the native gene by the combination of CAMP and ATRA in NB4 cells. As to the mechanism underlying the direct interaction between CAMP and ATRA on the LAP promoter, this may be the consequence of a direct PKA-dependent phosphorylation of the two RAR types, which are known to contain target sequences for the cyclic nucleotide-activated kinase." Phosphorylation of RAR-a and P m -R A R may alter the conformation of the two ligand-bound proteins and increase their transactivation potential." It is equally possible that phosphorylation of other factors involved in the transcription of LAP mRNA indirectly increases the activity of the promoter in cooperation with RARs. Interestingly, the promoter region of the UB/K-type alkaline phosphatase gene contains one or more functional RAREs, although their sequence has not yet been determined (this report and Heath et d"). By contrast, the promoter is devoid of CAMPresponsive elements (CREs), as the cyclic nucleotide alone does not increase the basal transcriptional activity of the gene itself. This suggests that the CAMP-responsive element binding protein (CREB/ATF)7' family of PKA-dependent transcriptional factors, which bind to CRE, are not involved in the cooperation between CAMP and ATRA at the level of the gene coding for LAP. We tend to favor the idea that direct phosphorylation of R A R s is involved in the cross-talk between the retinoid and the cAMP analogs, as stimulation of ATRAdependent transcription is observed also in artificial reporter genes consisting of very simple transcriptional units, such as the TRE-TK-CAT (Fig 7) . The fact that synergistic interaction between the cyclic nucleotide and the retinoid is observed also on TRE-TK-CAT suggests that this phenomenon may not be limited to the LAP promoter. This may be a more general characteristic shared by other ATRA-responsive gene products potentially expressed in normal and neoplastic myeloid cells.
Further studies are required to establish if the cross-talk between db-CAMP and ATRA is active only in the regulation of LAP in APL blasts or if it is a more general phenomenon involving other retinoid-regulated genes. Determination of these target genes may shed light on the molecular mechanisms underlying the process of granulocytic differentiation in both normal and leukemic cells. Nevertheless, the data presented in this report clearly demonstrate the capability of ATRA to interact with another cytodifferentiating agent, and this type of interaction may be exploited to obtain more efficient, and perhaps less toxic, differentiation of APL blasts in clinical settings. For personal use only. on November 11, 2017 . by guest www.bloodjournal.org From
